Company Description
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer.
It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers.
In addition, the company develops IO170, a TGFβ1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 2014 |
| IPO Date | Nov 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Mai-Britt Zocca |
Contact Details
Address: Ole MaalOees Vej 3, Copenhagen N Copenhagen, 2200 Denmark | |
| Phone | 45 70 70 29 80 |
| Website | iobiotech.com |
Stock Details
| Ticker Symbol | IOBT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001865494 |
| CUSIP Number | 449778109 |
| ISIN Number | US4497781090 |
| Employer ID | 87-0909276 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mai-Britt Zocca Ph.D. | Founder, President, Chief Executive Officer, Principal Financial Officer and Director |
| Amy B. Sullivan M.B.A. | Chief Financial Officer |
| Dr. Qasim Iftikhar Ahmad M.D. | Chief Medical Officer |
| Prof. Inge Marie Svane M.D., Ph.D. | Founder and Clinical Advisor |
| Prof. Mads Hald Andersen M.D., Ph.D. | Co-Founder and Scientific Advisor |
| Anders Ljungqvist | Founder |
| Prof. Per Thor Straten | Founder |
| Eric Faulkner M.B.A. | Chief Technical Officer |
| Devin Whittemore Smith J.D. | Secretary, General Counsel and Chief Compliance Officer |
| Daniel G. Mannix Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Dec 27, 2024 | 8-K | Current Report |